Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | GLA | P06280 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.48 |
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.45 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5483645 | 0.75 | ALDH1A1 (0.55) | KDM4EALDH1A1MAPTHPGDGLA | |
| SCHEMBL31115164 | 0.75 | ALDH1A1 (0.55) | KDM4EALDH1A1MAPTHPGDGLA | |
| SCHEMBL3486862 | 0.74 | KDM4E (0.44) | KDM4EALDH1A1MAPTHPGDGLA | |
| SCHEMBL9415849 | 0.74 | IKBKB (0.44) | KDM4EALDH1A1MAPTHPGDGLA | |
| SCHEMBL30248459 | 0.73 | ALDH1A1 (0.52) | KDM4EALDH1A1MAPTHPGDGLA | |
| SCHEMBL11173734 | 0.73 | ALDH1A1 (0.52) | KDM4EALDH1A1MAPTHPGDGLA | |
| SCHEMBL2781561 | 0.71 | KDM4E (0.50) | KDM4EALDH1A1MAPTHPGDGLA | |
| SCHEMBL2617034 | 0.71 | KDM4E (0.55) | KDM4EALDH1A1MAPTHPGDGLA | |
| SCHEMBL5245198 | 0.71 | KDM4E (0.55) | KDM4EALDH1A1MAPTHPGDGLA | |
| Hydrochloric Acid SCHEMBL21979894 | 0.71 | ALDH1A1 (0.50) | KDM4EALDH1A1MAPTHPGDGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3644992-B1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2023-03-29 | — | — | EP | claimed |
| US-4619861-A | COATING PARTICLES WITH ORGANONITROGEN OR ORGANOSULFUR POLYMER | TDK CORPORATION (JP) | 1986-10-28 | — | — | US | claimed |
| JP-5260986-A | — | — | None | — | — | JP | disclosed |
| EP-4735422-A1 | SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF TREATING PHENYLKETONURIA AND OTHER AMINO ACIDURIAS | Sanofi (FR) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025006827-A1 | SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF TREATING PHENYLKETONURIA AND OTHER AMINO ACIDURIAS | GENZYME CORPORATION (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240368170-A1 | CINNOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4259145-A1 | ALK-5 INHIBITORS AND USES THEREOF | Sumitomo Pharma Oncology, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| US-11746103-B2 | ALK-5 inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| EP-4225006-A2 | ORGANIC LIGHT-EMITTING DEVICE | Samsung Display Co., Ltd. (KR) | 2023-08-09 | — | — | EP | disclosed |
| CN-116546986-A | ALK-5 inhibitors and uses thereof | 住友制药肿瘤公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20220324880-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-1990010297-A1 | THERMALLY STABLE FORMS OF ELECTRICALLY CONDUCTIVE POLYANILINE | ALLIED-SIGNAL INC. (US) | 1990-09-07 | — | — | WO | disclosed |
| EP-0385735-A1 | Benzodiazepine analogs | BIOMEASURE, INC. (US) | 1990-09-05 | — | — | EP | disclosed |
| EP-0380517-A1 | THERMALLY STABLE FORMS OF ELECTRICALLY CONDUCTIVE POLYANILINE. | ALLIED SIGNAL INC (US) | 1990-08-08 | — | — | EP | disclosed |
| CN-1006386-B | PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER | SHINETSU CHEM IND CO (JP) | 1990-01-10 | — | — | CN | disclosed |
| WO-1989001694-A1 | THERMALLY STABLE FORMS OF ELECTRICALLY CONDUCTIVE POLYANILINE | ALLIED-SIGNAL INC. (US) | 1989-02-23 | — | — | WO | disclosed |
| CN-85107531-A | Process for producing vinyl chloride polymer | — | 1987-01-21 | — | — | CN | disclosed |
| US-4619861-A | COATING PARTICLES WITH ORGANONITROGEN OR ORGANOSULFUR POLYMER | TDK CORPORATION (JP) | 1986-10-28 | — | — | US | disclosed |
| US-4539230-A | COATING WALLS WITH A CHELATE COMPOUND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1985-09-03 | — | — | US | disclosed |
| EP-0126991-A1 | A method for preventing deposition of polymer scale and a coating agent therefor | Shin-Etsu Chemical Co., Ltd. (JP) | 1984-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368170-A1 | CINNOLINE COMPOUNDS AND USES THEREOF | HIPK1, CDC7, MAP3K7 | KDM4E 3429/4885ALDH1A1 2519/4885MAPT 4474/4885 |
| US-20220324880-A1 | SMARCA INHIBITORS AND USES THEREOF | SMARCA1, SMARCE1, PBRM1 | KDM4E 648/4885ALDH1A1 3223/4885MAPT 1576/4885 |
| US-11746103-B2 | ALK-5 inhibitors and uses thereof | ACVR1, ALK, ACVRL1 | KDM4E 664/4885ALDH1A1 773/4885MAPT 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.